Prostate cancer patients surveyed 5 years after vessel-sparing RT report preserved sexual function

(American Society for Radiation Oncology) A comparison of five-year sexual function outcomes, as reported by patients treated with external beam radiotherapy versus combination external beam radiotherapy plus brachytherapy, indicates that the utilization of vessel-sparing radiation therapy makes cure possible without compromising long-term sexual function, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news

Related Links:

Publication date: Available online 14 April 2018Source: Practical Radiation OncologyAuthor(s): Stephen A. Mihalcik, Jonathan J. Chipman, Martin G. Sanda, Meredith M. Regan, Irving D. Kaplan, Andrew A. Wagner, Catrina M. Crociani, Peter Chang, PROST-QA Consortium
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU Abstract PURPOSE: Gleason score (GS) 10 disease is the most aggressive form of clinically localized prostate adenocarcinoma (PCa). The long-term clinical outcomes and overall prognosis of patients presenting with GS 10 PCa are largely unknown because of its rarity. METHODS AND MATERIALS: The study included 112 patients with biopsy-determined GS 10 PCa who received treatment with radical prostatectomy (RP, n = 26), external bea...
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Int J Radiat Oncol Biol Phys Source Type: research
Publication date: Available online 14 April 2018Source: Practical Radiation OncologyAuthor(s): Stephen A. Mihalcik, Jonathan J. Chipman, Martin G. Sanda, Meredith M. Regan, Irving D. Kaplan, Andrew A. Wagner, Catrina M. Crociani, Peter Chang, PROST-QA Consortium
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
External beam radiation therapy plus a brachytherapy boost (BB) has been shown to offer a 20% improvement in biochemical-free survival compared to dose-escalated external beam radiation therapy for men with intermediate and high-risk prostate cancer, based on the recently published ASCENDE-RT trial. Nevertheless, a National Cancer Database analysis demonstrated a concerning decline in utilization of BB in this population between 2004 and 2013, despite an association with improved overall survival.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Publication date: Available online 14 April 2018 Source:Practical Radiation Oncology Author(s): Stephen A. Mihalcik, Jonathan J. Chipman, Martin G. Sanda, Meredith M. Regan, Irving D. Kaplan, Andrew A. Wagner, Catrina M. Crociani, Peter Chang
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
Men with localized prostate cancer treated with combined external beam therapy with low-dose rate brachytherapy prostate boost enrolled in a prospective population-based study reported worse bowel function at one year and worse urinary irritative function through three years compared to men treated with external beam radiation therapy alone. These side effect profiles should be discussed with patients considering combined external beam therapy with low-dose rate brachytherapy prostate boost.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research
Conclusions: 68Ga-PSMA-11 PET is sensitive for prostate cancer metastases in patients with biochemically recurrent prostate cancer, with high positive predictive value and excellent inter-rater reliability.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Posters Source Type: research
Localized prostate cancer is effectively managed with any of several treatment modalities including prostatectomy, radiation (external-beam radiation therapy [EBRT], CyberKnife [CK], brachytherapy), and cryotherapy. Patients with prostate cancer refractory to primary treatment may undergo salvage treatment to control their cancer recurrence. One such salvage treatment is cryotherapy, controlled freezing of the prostate. We sought to determine how the choice of primary treatment affects the risk of biochemical recurrence (BCR) following salvage cryotherapy treatment for refractory prostate cancer.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Localized: Ablative Therapy II Source Type: research
Localized prostate cancer (PCa) is mainly treated with both radical prostatectomy (RP) and radiation therapy. Radiation-induced secondary cancers are possible late-onset adverse events of radiation therapy. The incidence of secondary cancer increases at 10 or more years after completion of the radiation therapy. The secondary cancer varies among the types of radiation therapy, and it has been generally considered that the incidence is lower after brachytherapy alone than that after either external beam radiotherapy (EBRT) alone or brachytherapy combined with EBRT.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Localized: Radiation Therapy Source Type: research
We compared patient reported disease specific functional outcomes after external beam radiation therapy (EBRT) and combined EBRT with low-dose rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Localized: Radiation Therapy Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | External Beam Therapy | Health | International Medicine & Public Health | Prostate Cancer | Radiation Therapy